H.C. Wainwright

Neptune: Phase 2 Topline Win Welcomes Neptune Into Prescription Omega-3 League, Says H.C. Wainwright

In a research report released Friday, analyst Andrew Fein of H.C.

Scott Fields Scott Fields — October 3, 2014, 10:57 AM EDT

H.C. Wainwright Reiterates Buy On Keryx Following Initiation Of A New Phase 3 Study

In a research report released today to investors, H.C.

Ben Mahaney, Editor — September 30, 2014, 2:32 PM EDT

H.C. Wainwright Maintains Buy On Seattle Genetics On The Heels Of Positive Data From Phase 3

In a research note published today, H.C.

Corey Williams — September 30, 2014, 2:20 PM EDT

Scarcity Value Inherent In CPRX Story Remains Underappreciated, Says H.C. Wainwright

In a research note released today to investors, H.C.

Ben Mahaney, Editor — September 30, 2014, 2:02 PM EDT

H.C. Wainwright Reiterates Buy On Ariad Following Clinical Data On AP26113

In a research report released today, H.C.

Ben Mahaney, Editor — September 30, 2014, 1:10 PM EDT

Threshold: We Regard The IDMC Green Light Positively, Says H.C. Wainwright

In a research report issued today, analyst Andrew Fein of H.C.

Ben Mahaney, Editor — September 23, 2014, 4:04 PM EDT

H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS

In a research report issued today, H.C.

Scott Fields Scott Fields — September 23, 2014, 3:40 PM EDT

H.C. Wainwright Reiterates Buy On Oxigene Following Initiation Of Phase 2 Study

In a research report issued today, H.C.

Ben Mahaney, Editor — September 22, 2014, 2:50 PM EDT

CTI BioPharma: Partnership For Pixuvri Highlights Potential, Says H.C. Wainwright

In a research report issued today, H.C.

Ben Mahaney, Editor — September 17, 2014, 1:54 PM EDT

H.C. Wainwright Maintains Buy On Catalyst Pharma, Increases PT To $13

In a research note released yesterday, H.C.

Editor Ben Weinberg — September 16, 2014, 8:07 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts